{"product_id":"yakka-strength-yakka-strength-wolverine-stack-bpc157-tb500-capsule-peptide-bundle","title":"Yakka Strength Wolverine Stack — BPC-157 \u0026 TB-500","description":"\u003cp\u003eThe Yakka Strength Wolverine Stack is the brand's name for a capsule bundle of two research peptides, BPC-157 (Body Protection Compound 157, also sold as BPC157) and TB-500 (TB500, a synthetic fragment of thymosin beta-4). The name is a marketing label and is not a claim about what the peptides do. According to the brand's own product page, the bundle consists of two separate pots, BPC157 and TB500, each of 60 capsules at 250 mcg per capsule: 120 capsules and 15 mg of each peptide as labelled. Supplied to adults for laboratory research only and not for human consumption.\u003c\/p\u003e\u003cp\u003eThe listing is a convenience that lets the brand's two peptide pots be bought in one order. Nothing on this page claims that they act together or should be studied together, and Free Muscle publishes no stack or cycle guidance for any product. Each peptide is therefore described on its own below.\u003c\/p\u003e\u003ch2\u003eAbout the compounds in this bundle\u003c\/h2\u003e\u003ch3\u003eBPC-157\u003c\/h3\u003e\u003cp\u003eBPC-157 is a synthetic fifteen-amino-acid peptide based on a sequence from a human gastric protein. Almost all published work is rodent and cell research, largely from one Croatian group, covering animal models of gut, tendon, muscle and vascular injury. Its developers mention early trials in inflammatory bowel disease, but no controlled human trial has been published in full, and oral absorption is unproven. WADA lists it under S0 (non-approved substances). Compare brands on the \u003ca href=\"\/en-ro\/collections\/bpc-157\"\u003eBPC-157 collection page\u003c\/a\u003e.\u003c\/p\u003e\u003ch3\u003eTB-500 (Thymosin Beta-4 fragment)\u003c\/h3\u003e\u003cp\u003eTB-500 is the trade name for a synthetic fragment of thymosin beta-4, a 43-amino-acid actin-binding peptide found in most human and animal cells. Reviews of thymosin beta-4 cover preclinical wound, corneal and cardiac repair models and early clinical trials of the full peptide. TB-500 itself has no published human data. When anti-doping chemists at Ghent University analysed a TB-500 product in 2012, the peptide they identified was the N-terminally acetylated 17-23 segment of thymosin beta-4, written Ac-LKKTETQ, not the whole protein. WADA names thymosin beta-4 and its derivatives, including TB-500, under S2. Compare brands on the \u003ca href=\"\/en-ro\/collections\/tb-500\"\u003eTB-500 (Thymosin Beta-4 fragment) collection page\u003c\/a\u003e.\u003c\/p\u003e\u003ch3\u003eIdentifiers\u003c\/h3\u003e\u003ctable\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eIdentifier\u003c\/th\u003e\n\u003cth\u003eBPC-157\u003c\/th\u003e\n\u003cth\u003eThymosin beta-4 (parent of TB-500)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLength\u003c\/td\u003e\n\u003ctd\u003e15 amino acids\u003c\/td\u003e\n\u003ctd\u003e43 amino acids; TB-500 is a 7-residue acetylated fragment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular formula\u003c\/td\u003e\n\u003ctd\u003eC62H98N16O22\u003c\/td\u003e\n\u003ctd\u003eC212H350N56O78S\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular weight\u003c\/td\u003e\n\u003ctd\u003e1419.5 g\/mol\u003c\/td\u003e\n\u003ctd\u003eabout 4,963 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAS number\u003c\/td\u003e\n\u003ctd\u003e137525-51-0\u003c\/td\u003e\n\u003ctd\u003enot listed in our PubChem record\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePubChem CID\u003c\/td\u003e\n\u003ctd\u003e9941957\u003c\/td\u003e\n\u003ctd\u003e45382195\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003ch3\u003eWhat the published research reports\u003c\/h3\u003e\u003cp\u003eFor BPC-157, the most cited overview is a 2016 review by the originating Zagreb group, which gathers its own rodent findings on the gut, brain and blood vessels and proposes a brain-gut axis role. Its main limitation is that it reviews largely single-laboratory work. For thymosin beta-4, a 2012 review by Goldstein and colleagues describes actin binding, cell migration and repair findings in animal models and early human studies of the full-length protein applied to skin and eye. Neither review concerns this product or TB-500 as sold, and none of it is a claim about the bundle. The \u003ca href=\"\/en-ro\/blogs\/news\/bpc-157-what-research-shows\"\u003eBPC-157 research article\u003c\/a\u003e and the \u003ca href=\"\/en-ro\/blogs\/news\/tb-500-thymosin-beta-4-research-guide\"\u003eTB-500 and thymosin beta-4 research guide\u003c\/a\u003e go further.\u003c\/p\u003e\u003cp\u003eBoth peptides are supplied here in capsule form. Whether peptides survive the digestive tract in any meaningful quantity is an open question, discussed in our article \u003ca href=\"\/en-ro\/blogs\/news\/do-oral-peptides-work\"\u003eDo oral peptides actually work?\u003c\/a\u003e.\u003c\/p\u003e\u003ch2\u003eThis listing\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eBrand: Yakka Strength (third-party brand, \u003ca href=\"\/en-ro\/pages\/muscle-market\"\u003eMuscle Market\u003c\/a\u003e)\u003c\/li\u003e\n\u003cli\u003eCompounds: BPC-157 and TB-500 (thymosin beta-4 fragment)\u003c\/li\u003e\n\u003cli\u003eForm and pack size: two 60-capsule pots, one per peptide (120 capsules), as the brand's product page states; each with its own label\u003c\/li\u003e\n\u003cli\u003ePeptide content per capsule: 250 mcg BPC157 and 250 mcg TB500, read from the two facts panels (salt and TB-500 molecule not stated)\u003c\/li\u003e\n\u003cli\u003eTotals as labelled: 15 mg BPC157 and 15 mg TB500\u003c\/li\u003e\n\u003cli\u003eCOA: only where Yakka Strength supplies one for the batch held\u003c\/li\u003e\n\u003cli\u003eSold to adults aged 18 and over, for laboratory research only\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eThe two peptides are also listed singly as \u003ca href=\"\/en-ro\/products\/yakka-strength-yakka-strength-bpc157-peptide-capsules\"\u003eYakka Strength BPC-157 capsules\u003c\/a\u003e and \u003ca href=\"\/en-ro\/products\/yakka-strength-yakka-strength-tb500-peptide-capsules\"\u003eYakka Strength TB-500 capsules\u003c\/a\u003e.\u003c\/p\u003e\u003ch2\u003eBPC-157 and TB-500 in the UK: buying, legal status and what to check\u003c\/h2\u003e\u003cp\u003eSearches such as \"BPC157 TB500 UK\", \"buy TB 500 UK\" and \"TB 500 legal UK\" come down to three questions: is it lawful to sell, who is a credible supplier, and what the listing should prove.\u003c\/p\u003e\u003ch3\u003eLegal position\u003c\/h3\u003e\u003cp\u003eNone of the compounds on this page is a licensed medicine in the United Kingdom, none has been assessed by the MHRA and none is an authorised food supplement. Neither peptide is a controlled drug. They are supplied only as research materials, never for human consumption. Free Muscle supplies them to adults aged 18 and over for laboratory research only. There is no licensed product containing either peptide, so neither is available on prescription. BPC-157 is listed by WADA under S0 and TB-500 under S2, and both are prohibited at all times in tested sport. Buyers are responsible for the rules that apply to them. Our \u003ca href=\"\/en-ro\/blogs\/news\/what-are-sarms-the-2026-research-guide\"\u003eSARMs research guide\u003c\/a\u003e has more background.\u003c\/p\u003e\u003ch3\u003eWhat a trustworthy UK listing shows\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBoth compounds named separately\u003c\/strong\u003e, with the manufacturer identified, rather than a blend described only by a nickname.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eA lot or batch number\u003c\/strong\u003e on each container, because test results attach to batches, not to product names.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eA certificate of analysis for that batch\u003c\/strong\u003e, covering each peptide in the bundle.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eA stated strength\u003c\/strong\u003e per capsule for each peptide, or an honest note that none is given.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSale terms that match the law\u003c\/strong\u003e: adults only, laboratory use stated, and no usage instructions or promised effects.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eA traceable UK seller\u003c\/strong\u003e with tracked delivery, plain packaging and a written returns policy.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eHow this listing measures up\u003c\/h3\u003e\u003cp\u003eThe seller is named: FreeMuscle, registered in Andorra, with UK operations and dispatch in Scunthorpe. Each pot names its distributor, sales are restricted to adults and this page gives no directions for use. Every order ships by free tracked UK delivery in plain packaging, orders placed before 2pm Monday to Friday are processed the same working day, EU delivery takes 3 to 7 working days, and unopened items can be returned within 30 days. Each label gives a per-capsule strength, 250 mcg, so that check is met. The point that depends on Yakka Strength is the certificate, which appears only where one has been supplied for the batch we hold, one per pot. Our \u003ca href=\"\/en-ro\/blogs\/news\/how-to-choose-a-sarms-supplier-uk-checklist\"\u003eUK supplier checklist\u003c\/a\u003e sets out these checks in full, and delivery terms are on the \u003ca href=\"\/en-ro\/pages\/shipping\"\u003eshipping page\u003c\/a\u003e.\u003c\/p\u003e\u003ch2\u003eCapsules compared with other forms\u003c\/h2\u003e\u003cp\u003eBPC-157 and TB-500 are both offered as capsules or tablets, as freeze-dried powder in sealed vials, and occasionally as pre-mixed liquids. The research literature on both peptides relies overwhelmingly on injection: into the abdominal cavity or muscle in rodent studies of BPC-157, and by injection or topical application in thymosin beta-4 work. Some Zagreb experiments gave BPC-157 in drinking water, but no study has measured blood levels in people after an oral dose of either peptide.\u003c\/p\u003e\u003cp\u003eThe obstacle for any swallowed peptide is enzymatic. Pepsin in the stomach and trypsin, chymotrypsin and brush-border peptidases in the small intestine cleave peptide bonds, and short linear chains such as a 15-residue or 7-residue peptide are ordinary substrates. The originating group reports that BPC-157 resists human gastric juice in its own tests; no equivalent claim has been published for the TB-500 fragment. Whether either survives in meaningful amounts is unresolved, which is the subject of \u003ca href=\"\/en-ro\/blogs\/news\/bpc-157-capsules-vs-injection-what-studies-used\"\u003eBPC-157 capsules vs injection: what the studies used\u003c\/a\u003e.\u003c\/p\u003e\u003cp\u003eAs materials, the formats behave differently. Dry powder, in a capsule or sealed vial, is more stable than peptide in solution. Fill accuracy is another difference: a capsule's content depends on how evenly the powder was blended with filler before encapsulation, while a liquid's depends on how accurately it was made up and measured. None of this implies that any format produces an effect.\u003c\/p\u003e\u003ch2\u003eBPC-157 compared with TB-500\u003c\/h2\u003e\u003cp\u003e\"TB 500 vs BPC 157\" is the comparison searched most often for this pair. Though often sold side by side, they are unrelated, with different parent proteins, different research traditions and different anti-doping classifications.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrigin.\u003c\/strong\u003e BPC-157 is a 15-residue sequence (GEPPPGKPADDAGLV) derived from a protein in gastric juice. TB-500 is built around residues 17 to 23 of thymosin beta-4, the segment linked to actin binding.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProposed mechanism.\u003c\/strong\u003e Work on BPC-157 points to growth factor, nitric oxide and cell-signalling pathways in rodent tissue. Thymosin beta-4 is best known for holding a pool of unpolymerised actin, which influences how cells migrate.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eEvidence base.\u003c\/strong\u003e BPC-157 has rodent and cell studies, mostly from one research network, and no published randomised human trial. Thymosin beta-4 has animal studies from many laboratories and small early human trials of the full protein; the TB-500 fragment itself has none.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory status.\u003c\/strong\u003e Both are unlicensed research compounds in the UK, with no approval from the MHRA, EMA or FDA.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWADA class.\u003c\/strong\u003e S0 for BPC-157, as a substance with no therapeutic approval; S2 for TB-500, because the list names thymosin beta-4 and its derivatives.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eIs TB-500 the same as thymosin beta-4?\u003c\/h3\u003e\u003cp\u003eNo, although the names are often used interchangeably. Thymosin beta-4 is the whole 43-residue protein, about 4,963 g\/mol. The product sold as TB-500 was shown by laboratory analysis to contain the acetylated seven-residue fragment Ac-LKKTETQ, a far smaller molecule. No human study has compared BPC-157 with TB-500, so neither can be ranked above the other, and we give no guidance on studying them together. Single-compound listings are on the \u003ca href=\"\/en-ro\/collections\/tb-500\"\u003eTB-500 collection\u003c\/a\u003e and \u003ca href=\"\/en-ro\/collections\/bpc-157\"\u003eBPC-157 collection\u003c\/a\u003e pages, and the wider class is covered in \u003ca href=\"\/en-ro\/blogs\/news\/sarms-vs-peptides-choosing-by-goal\"\u003eSARMs vs peptides\u003c\/a\u003e.\u003c\/p\u003e\u003ch2\u003eReading the certificate of analysis for this product\u003c\/h2\u003e\u003cp\u003eYakka Strength is a third-party brand sold through Muscle Market. Third-party certificates of analysis are displayed only when the brand has handed one over for the exact batch we hold, and here that means one per pot; if none is shown, none has been supplied and we do not substitute a generic document. Free Muscle-brand products, by contrast, are assayed batch by batch at Janoshik Analytical, with the certificate sent on request by email, as with our own \u003ca href=\"\/en-ro\/collections\/bpc-150\"\u003eBPC-150 capsules\u003c\/a\u003e. That testing does not extend to Yakka Strength.\u003c\/p\u003e\u003cp\u003eA certificate covering one peptide says nothing about the other, so read each line against the pack:\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompound named.\u003c\/strong\u003e The report should say whether it covers BPC-157, TB-500 or both, and which container it belongs to.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIdentity method.\u003c\/strong\u003e HPLC compares retention time with a reference standard; LC-MS also measures molecular mass. For TB-500, the mass found should match the small acetylated fragment, not the full thymosin beta-4 protein, which is one of the clearest identity checks available.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity percentage.\u003c\/strong\u003e How much of the detected material is the named peptide rather than synthesis by-products; a high figure says nothing about the quantity in a capsule.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eContent per capsule.\u003c\/strong\u003e The only figure that could supply the strength missing from this label. It should say whether it reports net peptide or total powder.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBatch number and test date.\u003c\/strong\u003e These must match the lot printed on the container and show how recent the analysis is.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLaboratory name.\u003c\/strong\u003e An unnamed lab cannot be asked to confirm that it issued the report.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eFor this brand, a missing field matters directly: with no content line the labelled 250 mcg stays unverified, and a report without a batch number cannot be linked to the capsules in hand. To ask what exists for current stock, send the batch number on the pack through our \u003ca href=\"\/en-ro\/pages\/contact\"\u003econtact page\u003c\/a\u003e. Our \u003ca href=\"\/en-ro\/pages\/lab-tests\"\u003elab testing page\u003c\/a\u003e explains what a certificate shows, and \u003ca href=\"\/en-ro\/blogs\/news\/how-to-read-a-certificate-of-analysis\"\u003ehow to read a certificate of analysis\u003c\/a\u003e works through an example.\u003c\/p\u003e\u003ch2\u003eDetection, sport and testing\u003c\/h2\u003e\u003cp\u003eBoth peptides are prohibited at all times, in and out of competition, under the World Anti-Doping Code, which UK Anti-Doping applies in the UK. BPC-157 is named in S0, the class for substances with no current approval for human therapeutic use. TB-500 falls under S2 through thymosin beta-4 and its derivatives. Strict liability applies, so an athlete is responsible for whatever is found in a sample, whatever the label said.\u003c\/p\u003e\u003cp\u003eAnti-doping laboratories have published methods for each. In 2012 the Ghent doping control laboratory identified Ac-LKKTETQ in a TB-500 product by high-resolution mass spectrometry, synthesised a reference standard and proposed a strategy for finding it in plasma and urine. In 2017 the Salt Lake City laboratory validated a urine test for BPC-157 with a limit of detection of 0.1 ng\/mL, found the peptide stable in urine for at least four days, and improved specificity by measuring a stable metabolite as well. Neither study established how long either peptide stays detectable after human exposure, so the accurate position for both is detectable, window not established.\u003c\/p\u003e\u003ch2\u003eStorage, stability and handling\u003c\/h2\u003e\u003cp\u003eNo published stability study covers BPC-157 or TB-500 in capsule form, so the expiry or best-before date printed by the manufacturer, if there is one, is the limit to observe. General peptide chemistry indicates the main risks. Water drives hydrolysis of peptide bonds and makes powder clump and gelatin shells soften. Heat speeds up degradation and some amino acids oxidise over time, a process that light can accelerate.\u003c\/p\u003e\u003cp\u003eKeep each container tightly closed in a cool, dry, dark cupboard, away from heaters and steamy rooms, with any desiccant left in place. If a container is refrigerated, allow it to reach room temperature before opening so moisture does not condense inside. Keep capsules in the original container that carries the batch number, so they can still be matched to a certificate. Handle the contents as laboratory reagents: gloves when working with opened capsules, separation from food and drink, storage out of reach of children and pets, and disposal as chemical waste rather than down a drain.\u003c\/p\u003e\u003ch2\u003eGlossary\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eActin\u003c\/strong\u003e: a structural protein inside cells; thymosin beta-4 binds its unpolymerised form.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAcetylation\u003c\/strong\u003e: addition of an acetyl group, here to the start of the TB-500 fragment, marked \"Ac-\" in its sequence.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProtease\u003c\/strong\u003e: an enzyme that cuts peptide bonds, found throughout the digestive tract.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRetention time\u003c\/strong\u003e: how long a compound takes to pass through a chromatography column, used to match it to a standard.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigh-resolution mass spectrometry\u003c\/strong\u003e: measurement of molecular mass precise enough to separate compounds of very similar weight.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eS0 and S2\u003c\/strong\u003e: WADA Prohibited List sections for non-approved substances and for hormones, growth factors and related substances.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrict liability\u003c\/strong\u003e: the anti-doping rule that an athlete answers for any prohibited substance in a sample.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAbout the Yakka Strength Wolverine Stack\u003c\/h2\u003e\n\u003cp\u003e\"Wolverine Stack\" is the only product name in the Yakka Strength research range that is not simply a compound name, and it is the one bundle whose listing text gives the strength as well as the pot count: two products, BPC157 capsules and TB500 capsules, each 60 capsules per container at 250 mcg per capsule. In the box that means the brand's two purple-lettered peptide pots, each with its own facts panel (250 mcg per capsule, 60 capsules, \"Made in the UK\") and its own back panel naming Yakka Strength Ltd as distributor: 120 capsules, 15 mg of each peptide as labelled. The name is a product name and we attach no meaning to it. Neither label names a salt for BPC157 or says which thymosin beta-4 molecule the TB500 pot holds.\u003c\/p\u003e\n\u003cp\u003eThe company behind the brand, Yakka Strength Ltd, appears on the Companies House register (number 13284431, County Durham, incorporated 2021); gym equipment and sports nutrition are its main trade, and the brand traces its name to \"Pit Yakka\", local slang for a miner. Its research capsules run to eleven items, all on the \u003ca href=\"\/en-ro\/collections\/brand-yakka-strength\"\u003eYakka Strength brand page\u003c\/a\u003e. The two pots here are the brand's \u003ca href=\"\/en-ro\/products\/yakka-strength-yakka-strength-bpc157-peptide-capsules\"\u003eBPC-157\u003c\/a\u003e and \u003ca href=\"\/en-ro\/products\/yakka-strength-yakka-strength-tb500-peptide-capsules\"\u003eTB-500\u003c\/a\u003e pots, also sold singly and also found in the \u003ca href=\"\/en-ro\/products\/yakka-strength-yakka-strength-mk677-bpc157-tb500-capsule-bundle\"\u003ethree-pot bundle\u003c\/a\u003e with MK677. Yakka Strength's site publishes no test results and identifies neither manufacturer nor laboratory, so verification is per pot: read each container's lot number (the label artwork has none), ask us which documents the brand has supplied per batch, and look for an identity result before a content figure.\u003c\/p\u003e\n\u003cp\u003eBoth are research peptides with no medicines licence anywhere and no UK supplement authorisation; WADA puts BPC-157 in section S0, while its section S2 covers thymosin beta-4 derivatives such as TB-500. On label figures alone, \u003ca href=\"\/en-ro\/collections\/brand-thoroughbred-labs\"\u003eThoroughbred Labs\u003c\/a\u003e states 300 mcg per capsule for both its BPC-157 and its TB-500 capsules, and \u003ca href=\"\/en-ro\/collections\/brand-biolab\"\u003eBioLab\u003c\/a\u003e 200 mcg for its BPC-157 hydrochloride; no other brand we stock sells the two peptides as a pair. The \u003ca href=\"\/en-ro\/collections\/bpc-157\"\u003eBPC-157\u003c\/a\u003e and \u003ca href=\"\/en-ro\/collections\/tb-500\"\u003eTB-500\u003c\/a\u003e collections carry the brand-by-brand tables.\u003c\/p\u003e\n\u003ch2\u003eRelated\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\u003ca href=\"\/en-ro\/collections\/bpc-157\"\u003eBPC-157 collection\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"\/en-ro\/collections\/tb-500\"\u003eTB-500 (Thymosin Beta-4) collection\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"\/en-ro\/collections\/brand-yakka-strength\"\u003eYakka Strength brand page\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"\/en-ro\/collections\/peptides\"\u003ePeptides collection\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"\/en-ro\/collections\/market-bundles\"\u003eBundles collection\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003ca href=\"\/en-ro\/pages\/shipping\"\u003eDelivery\u003c\/a\u003e and \u003ca href=\"\/en-ro\/pages\/guarantee\"\u003ereturns\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cem\u003eResearch compounds sold by Free Muscle are supplied for laboratory research use only and are not for human consumption. They are not authorised as medicines by the MHRA, EMA or FDA, are not food supplements, and are sold only to adults aged 18 or over. Nothing on this page is medical or dosing advice. Summaries of published research describe study findings and are not claims about any product.\u003c\/em\u003e\u003c\/p\u003e\u003ch2\u003eReferences\u003c\/h2\u003e\u003col\u003e\n\u003cli\u003eSikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27138887\/\" rel=\"noopener\"\u003ePMID: 27138887\u003c\/a\u003e.\u003c\/li\u003e\n\u003cli\u003eGoldstein AL, et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22074294\/\" rel=\"noopener\"\u003ePMID: 22074294\u003c\/a\u003e.\u003c\/li\u003e\n\u003cli\u003eEsposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22962027\/\" rel=\"noopener\"\u003ePMID: 22962027\u003c\/a\u003e.\u003c\/li\u003e\n\u003cli\u003eCox HD, et al. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490-1498. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28035768\/\" rel=\"noopener\"\u003ePMID: 28035768\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"Yakka Strength","offers":[{"title":"Default Title","offer_id":48468983021794,"sku":null,"price":89.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0772\/3499\/5426\/files\/yakka-strength-wolverine-stack-bpc157-tb500-capsule-peptide-bundle-pack-shot-white.jpg?v=1791052926","url":"https:\/\/freemuscle.co.uk\/en-ro\/products\/yakka-strength-yakka-strength-wolverine-stack-bpc157-tb500-capsule-peptide-bundle","provider":"Free Muscle","version":"1.0","type":"link"}